Business
The current state of political affairs in the U.S. does not bode well for the direction of that turn. The country is at real risk of losing its long-held lead in biotech innovation.
FEATURED STORIES
The rare disease drugmaker is facing potential competitors for achondroplasia drug Voxzogo. Is a big M&A deal with two approved assets enough to maintain investor interest?
A rapturous response to data published last year for Pelage’s hair loss candidate overwhelmed the biotech. Now, the company is ready to show the world the science behind the breakthrough.
Pfizer, Eli Lilly, Novartis, Bristol Myers Squibb and AstraZeneca are all ramping up the use of AI, but drug discovery is not the primary success story—yet.
Subscribe to BioPharm Executive
Market insights and trending stories for biopharma leaders, in your inbox every Wednesday
THE LATEST
Lysogene and Sarepta Therapeutics will end a licensing agreement after failed discussions of transferring global commercial supply rights for the LYS-SAF302 asset back to Lysogene.
The companies believe the collaboration, valued at more than $1.5 billion, for up to three small molecule therapeutics has the potential to transform oncology treatments.
Imcyse’s peptides work by priming cytolytic T cells to recognize and destroy those immune cells attacking the pancreas beta cells.
Since Rallybio launched in 2018, the company has been laser-focused on the development of “transformative therapeutics” for patients suffering from rare and ultra-rare diseases.
Protein degradation, cell therapy, synergistic combinations and changes in personalized cancer therapies will drive the next generation of therapeutics...
Biopharma and life sciences companies from across the globe provide updates to their businesses and pipelines.
The job cuts were announced as part of an organizational streamlining initiative that will refocus resources toward the company’s highest-value activities.
BioSpace takes a look at the presentations made by Amgen, GSK and 2sevent bio at the all-virtual J.P. Morgan Conference.
Daiichi wants to maximize its investment in three antibody-drug conjugates, which the company has positioned as one of the strategic pillars of its 5-year Business Plan.
Pfizer is cutting its sales staff as physicians and healthcare facilities prefer fewer face-to-face interactions with vendors due to the COVID-19 pandemic.